Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

5572 - A risk score integrating lymphocytes ratios (LRs) and lactate dehydrogenase (LDH) levels to predict prognosis in metastatic breast cancer (MBC) patients.

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Targeted Therapy

Tumour Site

Breast Cancer

Presenters

Giacomo Pelizzari

Citation

Annals of Oncology (2018) 29 (suppl_8): viii90-viii121. 10.1093/annonc/mdy272

Authors

G. Pelizzari1, L. Gerratana1, D. Basile1, S. Zago2, M.G. Vitale1, M. Bartoletti1, C. Lisanti1, V. Fanotto1, C. Corvaja1, L. Bortot1, A. Liguori3, M. Cinausero1, S. Russo4, C. Andreetta4, M. Bonotto4, M. Mansutti4, A.M. Minisini4, F. Curcio5, G. Fasola4, F. Puglisi6

Author affiliations

  • 1 Department Of Medicine (dame), University of Udine, 33100 - Udine/IT
  • 2 Clinical Pathology, Hospital “Santa Maria degli Angeli”, 33170 - Pordenone/IT
  • 3 Medical Oncology Unit, Department Of Human Pathology "g. Barresi", AOU Policlinico G. Martino Università di Messina, 98125 - Messina/IT
  • 4 Department Of Oncology, ASUIUD Santa Maria della Misericordia, 33100 - Udine/IT
  • 5 Clinical Pathology Institute, ASUIUD Santa Maria della Misericordia, 33100 - Udine/IT
  • 6 University Of Udine - Udine, Italy; Department Of Medical Oncology And Cancer Prevention, CRO National Cancer Institute, 33081 - Aviano/IT
More

Resources

Abstract 5572

Background

Monocyte-to-lymphocyte ratio (MLR), neutrophil-to-lymphocyte ratio (NLR) and LDH levels have been associated with worse prognosis in several malignancies, including MBC. This study aimed at exploring the prognostic impact of a novel risk score, integrating baseline LRs and LDH levels in MBC patients (pts).

Methods

This retrospective study analyzed 396 consecutive pts with a diagnosis of MBC, treated between 2007 and 2017 at the Oncology Department of Udine (Italy). MLR and NLR cut-offs were previously obtained through ROC analysis using propensity score-matched healthy controls (Gerratana et al 2018). The LDH cut-off value (480 U/L) was chosen according to the local laboratory upper reference limit. Based on these data, an integrated LRs-LDH score (LLS) was calculated ranging from 0 (LRs and LDH low), through 1 (LRs or LDH high), to 2 (both LRs and LDH high). The prognostic impact of baseline LLS was investigated through Cox regression, and differences in survival were tested by log-rank test.

Results

After a median follow-up of 52.8 months, median overall survival (OS) was 30.9 months and median progression free survival (PFS) was 9.2 months. Pts with baseline elevated MLR, NLR or LDH were 64.2% (251/391), 70.8% (277/391), and 31.5% (70/222), respectively. The 78.8% (308/391) of pts had elevated LRs (MLR, NLR or both). Considering subgroup analysis, no interaction was seen between LDH and LRs. By multivariate analysis, after adjustment for molecular profiles, performance status, number of metastatic sites, central nervous system and liver involvement, a worse prognosis in terms of OS was seen for pts with elevated levels of both LRs and LDH (LLS 2: HR 2.41, 95% CI: 1.31-4.37, p=.003), compared to pts with normal LRs and LDH (LLS 0). Notably, significant differences in OS were observed according to the LLS (LLS 2: median OS 19.2 months, LLS 1: median OS 43.9 months, LLS 0: median OS 54.9 months; p<.0001).

Conclusions

Baseline LLS is able to predict survival in pts with MBC and provides independent prognostic information. Prospective studies are needed to validate this novel score and to explore how it may affect different treatment strategies.

Clinical trial identification

Legal entity responsible for the study

University of Udine.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.